Oncology (all articles)
The Role of End-of-life Palliative Sedation: Medical and Ethical Aspects
4 Jan, 2019 | 20:38h | UTC
Study: Risk of Solid Subsequent Malignant Neoplasms after Childhood Hodgkin Lymphoma
4 Jan, 2019 | 20:30h | UTCCommentary: High Long-Term Risk of Solid Cancers in Survivors of Childhood Hodgkin Lymphoma – The ASCO Post (free)
Study: CAR-T cell Therapy Evaluated for Refractory Diffuse Large B-Cell Lymphoma
4 Jan, 2019 | 20:28h | UTCTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma – University of Chicago Medical Center (free)
Randomized Trial: Treatments for Relapsed Glioblastoma Compared
4 Jan, 2019 | 20:27h | UTCRegorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Regorafenib vs Lomustine in Relapsed Glioblastoma – The ASCO Post (free)
Randomized Trial: Short- vs Intermediate-Term Androgen Suppression, With or Without Zoledronic Acid, in Men with Locally Advanced Prostate Cancer
4 Jan, 2019 | 19:35h | UTCShort-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: RADAR Trial: Short- vs Intermediate-Term Androgen Suppression and Zoledronic Acid in Locally Advanced Prostate Cancer – The ASCO Post (free)
New Article: 10-year results from the TROG 03.04 RADAR trial on short-term vs intermediate-term #androgen suppression & #radiotherapy +/– zoledronic acid for locally advanced #prostatecancer https://t.co/GGPqEv2UtA
— The Lancet Oncology (@TheLancetOncol) December 20, 2018
Meta-Analysis: Neoadjuvant Chemoradiation Treatment for Resectable Esophago-Gastric Cancer
4 Jan, 2019 | 19:30h | UTC
Randomized Trial: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
4 Jan, 2019 | 19:13h | UTCMaintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Results Reported for Olaparib Maintenance in Ovarian Cancer – The ASCO Post (free) AND Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer – Cancer Therapy Advisor (free)
Consensus: Management of Tyrosine Kinase Inhibitor-associated Side Effects in Gastrointestinal Stromal Tumors
4 Jan, 2019 | 19:14h | UTC
Cholangiocarcinoma: A Guide for the Nonspecialist
4 Jan, 2019 | 19:02h | UTCCholangiocarcinoma: a guide for the nonspecialist – International Journal of General Medicine (free)
Meta-Analysis: Current Chemotherapy Regimens in Advanced Pancreatic Cancer
4 Jan, 2019 | 18:50h | UTC
Treatment of Pain in Cancer: Towards Personalized Medicine
4 Jan, 2019 | 18:26h | UTCTreatment of Pain in Cancer: Towards Personalised Medicine – Cancers (free)
Review: Management of Sub-centimeter Recurrent Hepatocellular Carcinoma After Curative Treatment
4 Jan, 2019 | 18:24h | UTC
Consensus Statement: Multidisciplinary Workflow Algorithms for the Evaluation and Management of Thyroid Nodules
4 Jan, 2019 | 18:20h | UTC
Guideline: Sentinel Lymph Node Localization in Oral Cavity Squamous Cell Carcinoma
3 Jan, 2019 | 11:55h | UTC
SEOM Guideline: Diagnosis and Treatment of Metastatic Colorectal Cancer
3 Jan, 2019 | 11:44h | UTC
SEOM Guideline: Treatment of Muscle-invasive and Metastatic Urothelial Bladder Cancer
3 Jan, 2019 | 11:45h | UTC
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
3 Jan, 2019 | 11:34h | UTCCommentary: FDA Issues Guidance on Endpoints for Cancer Clinical Trials – The ASCO Post (free)
Review: Contemporary Approach to Active Surveillance for Favorable Risk Prostate Cancer
3 Jan, 2019 | 11:13h | UTC
Randomized Trial: Radical Prostatectomy vs. Watchful Waiting in Prostate Cancer
13 Dec, 2018 | 23:58h | UTCRadical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Long-term study shows most prostate cancer patients don’t need aggressive treatment – STAT (free) AND Radical surgery for some prostate cancers adds three years to life – Reuters (free)
Randomized Trial: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
13 Dec, 2018 | 19:05h | UTCOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer – NEJM Journal Watch (free) AND Durvalumab Shows Overall Survival Benefit in Patients With Stage III NSCLC – Cancer Therapy Advisor (free)
Review: Immune-related Adverse Events of Immune Checkpoint Inhibitors
13 Dec, 2018 | 19:02h | UTCImmune-related adverse events of immune checkpoint inhibitors: a brief review – Current Oncology (free)
Related: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (free) AND Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (free) AND New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management – Critical Care (free)
Review: Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
13 Dec, 2018 | 18:50h | UTCImmune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer – Chest (free)
Review: Clinical Efficacy of Immune Checkpoint Inhibitors in the Treatment of Unresectable Advanced or Recurrent Gastric Cancer
13 Dec, 2018 | 18:47h | UTC
Practical Integration of the ASCO Guidelines for Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
13 Dec, 2018 | 18:31h | UTCRelated Guidelines and Reviews: Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline (free) AND 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (free) AND Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy (free) AND Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia (free) AND Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management – CA: A Cancer Journal for Clinicians (free)
Review: Empirical Antimicrobial Treatment in Hemato-/Oncological Patients with Neutropenic Sepsis
13 Dec, 2018 | 18:15h | UTCRelated Guidelines: SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018) – Clinical and Translational Oncology (free) AND Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update – Journal of Clinical Oncology (free) AND Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) (free) AND Management of febrile neutropaenia: ESMO Clinical Practice Guidelines (free) AND Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update (free)